Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference
Minerva Neurosciences, a clinical-stage biopharmaceutical company focused on CNS disorders, will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021, at 11:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Minerva Neurosciences, a clinical-stage biopharmaceutical company focused on CNS disorders, will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021, at 11:00 a.m. ET. The event will be accessible through a live and archived webcast on the company's investor relations website. Minerva's portfolio includes roluperidone (MIN-101), in clinical trials for schizophrenia, and MIN-301, in pre-clinical development for Parkinson's disease. The stock is listed on NASDAQ under the symbol NERV.
Details
News Market Reaction – NERV
The recorded move for NERV in the trading session of this news was -0.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021 at 11:00 a.m. Eastern Time.
The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.
About Minerva Neurosciences
Minerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.